We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing
Read MoreHide Full Article
In the latest close session, Pfizer (PFE - Free Report) was up +1.17% at $24.31. The stock outpaced the S&P 500's daily gain of 1.11%. Meanwhile, the Dow gained 1.19%, and the Nasdaq, a tech-heavy index, added 1.43%.
The drugmaker's shares have seen an increase of 3.04% over the last month, surpassing the Medical sector's gain of 2.14% and falling behind the S&P 500's gain of 3.92%.
Investors will be eagerly watching for the performance of Pfizer in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $0.57, marking a 5% fall compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $13.55 billion, up 2% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $3.06 per share and revenue of $63.25 billion. These totals would mark changes of -1.61% and -0.6%, respectively, from last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Pfizer. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. At present, Pfizer boasts a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Pfizer has a Forward P/E ratio of 7.85 right now. For comparison, its industry has an average Forward P/E of 13.6, which means Pfizer is trading at a discount to the group.
Meanwhile, PFE's PEG ratio is currently 0.87. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 1.22.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 96, putting it in the top 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing
In the latest close session, Pfizer (PFE - Free Report) was up +1.17% at $24.31. The stock outpaced the S&P 500's daily gain of 1.11%. Meanwhile, the Dow gained 1.19%, and the Nasdaq, a tech-heavy index, added 1.43%.
The drugmaker's shares have seen an increase of 3.04% over the last month, surpassing the Medical sector's gain of 2.14% and falling behind the S&P 500's gain of 3.92%.
Investors will be eagerly watching for the performance of Pfizer in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $0.57, marking a 5% fall compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $13.55 billion, up 2% from the year-ago period.
Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $3.06 per share and revenue of $63.25 billion. These totals would mark changes of -1.61% and -0.6%, respectively, from last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Pfizer. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. At present, Pfizer boasts a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Pfizer has a Forward P/E ratio of 7.85 right now. For comparison, its industry has an average Forward P/E of 13.6, which means Pfizer is trading at a discount to the group.
Meanwhile, PFE's PEG ratio is currently 0.87. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 1.22.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 96, putting it in the top 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.